

UNITED STATES OF AMERICA  
Before the  
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934  
Release No. 69689 / June 4, 2013

ADMINISTRATIVE PROCEEDING  
File No. 3-15287

---

In the Matter of

BIOPHARM ASIA, INC.

:  
: ORDER MAKING FINDINGS AND  
: REVOKING REGISTRATION BY  
: DEFAULT

---

The Securities and Exchange Commission (Commission) instituted this proceeding with an Order Instituting Administrative Proceedings (OIP) on April 19, 2013, pursuant to Section 12(j) of the Securities Exchange Act of 1934 (Exchange Act). The OIP alleges that Respondent Biopharm Asia, Inc. (Biopharm Asia), repeatedly failed to file timely periodic reports with the Commission, in violation of Section 13(a) of the Exchange Act and Rules 13a-1 and 13a-13 thereunder.

The Division of Enforcement provided evidence that Biopharm Asia was served with the OIP on April 24, 2013, in accordance with Rules 141(a)(2)(ii) and (iv) of the Commission's Rules of Practice. See 17 C.F.R. § 201.141(a)(2)(ii), (iv). An Answer was due twenty days after service of the OIP. OIP at 2; 17 C.F.R. §§ 201.160(b), .220(b). On May 21, 2013, Biopharm Asia was ordered to show cause, by May 31, 2013, why the registration of its securities should not be revoked by default. To date, Biopharm Asia has not filed an Answer or responded to the Order to Show Cause.

Biopharm Asia is in default for failing to file an Answer, respond to the Order to Show Cause, or otherwise defend the proceeding. See OIP at 2-3; 17 C.F.R. §§ 201.155(a)(2), .220(f). Accordingly, as authorized by Rule 155(a) of the Commission's Rules of Practice, I find the following allegations in the OIP to be true.

Biopharm Asia, Central Index Key No. 1080908, is a Nevada corporation located in Jilin Province, China, as reflected in its last periodic filing. It has a class of securities registered with the Commission pursuant to Exchange Act Section 12(g). Biopharm Asia is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed its Form 10-Q for the period ended September 30, 2010, on November 12, 2010. As of April 5, 2013, Biopharm Asia's common stock (symbol "BFAR") was quoted on OTC Link (formerly, "Pink Sheets") operated by OTC Markets Group Inc., had ten market makers, and was eligible for the "piggyback" exception of Exchange Act Rule 15c2-11(f)(3).

In addition to repeated failures to file timely periodic reports, Biopharm Asia has failed to heed a delinquency letter sent to it by the Division of Corporation Finance requesting compliance with its periodic filing obligations or, through its failure to maintain a valid address on file with the Commission as required by Commission rules, did not receive such letter.

Section 13(a) of the Exchange Act and Rules 13a-1 and 13a-13 thereunder require issuers of securities registered pursuant to Section 12 of the Exchange Act to file with the Commission current and accurate information in periodic reports, even if the registration is voluntary under Section 12(g). Specifically, Rule 13a-1 requires issuers to file annual reports, and Rule 13a-13 requires domestic issuers to file quarterly reports. 17 C.F.R. §§ 240.13a-1, .13a-13.

As a result of the foregoing, Biopharm Asia has failed to comply with Section 13(a) of the Exchange Act and Rules 13a-1 and 13a-13 thereunder. Considering this delinquency, it is necessary and appropriate for the protection of investors to revoke the registration of each class of registered securities of Biopharm Asia.

### **ORDER**

It is ORDERED that, pursuant to Section 12(j) of the Securities Exchange Act of 1934, the registration of each class of registered securities of Biopharm Asia, Inc., is hereby REVOKED.

---

Cameron Elliot  
Administrative Law Judge